Holen Sie sich die Stockscreener-App
3.44
3.64%
-0.13
Handel nachbörslich:
3.44
Schlusskurs vom Vortag:
$3.57
Offen:
$3.57
24-Stunden-Volumen:
55,576
Relative Volume:
1.16
Marktkapitalisierung:
$32.27M
Einnahmen:
$2.57M
Nettoeinkommen (Verlust:
$-13.54M
KGV:
-0.6156
EPS:
-5.5882
Netto-Cashflow:
$-23.50M
1W Leistung:
-7.28%
1M Leistung:
+10.97%
6M Leistung:
-14.43%
1J Leistung:
-88.17%
1-Tages-Spanne:
$3.29
$3.59
1-Wochen-Bereich:
$3.29
$4.04
52-Wochen-Spanne:
$2.75
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.44 | 33.49M | 2.57M | -13.54M | -23.50M | -5.5882 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser
Tvardi Therapeutics to Participate in Upcoming Investor Events - Yahoo Finance
What Tvardi Therapeutics (TVRD)'s +1.01% Jump Means for Investors 2026-05-17Market Neutral Pair - Newser
[EFFECT] Tvardi Therapeutics, Inc. SEC Filing - Stock Titan
JonesTrading Maintains Tvardi Therapeutics(TVRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Number of shareholders of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
593,758 resale shares by Tvardi Therapeutics (NASDAQ: TVRD) post‑merger - Stock Titan
Tvardi Therapeutics 4Q Research and Development Expenses $4.9M >TVRD - Moomoo
Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Tvardi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
Tvardi Therapeutics 1Q 2026: Revenue ($6.81M), Net income ($6.8M), EPS ($0.73) — 10-Q Summary - TradingView
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Net loss narrowed to $6.8M, but continued operations depend on securing additional funding - TradingView
Tvardi Therapeutics: Net loss narrowed in Q1 2026 as clinical milestones for TTI-109 and TTI-101 approach - TradingView
Tvardi: Q1 Earnings Snapshot - marketscreener.com
Tvardi Therapeutics (NASDAQ: TVRD) posts Q1 2026 loss and warns on going concern - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) narrows Q1 loss and targets 2026 STAT3 trial readouts - Stock Titan
Two biotech readouts ahead as Tvardi says cash lasts into Q4 - Stock Titan
The key risks discussed in Tvardi Therapeutics (TVRD) earnings | Q4 2025: EPS Misses ViewsRevenue Report - Newser
Tvardi Therapeutics Files $200 Million Mixed Shelf - Moomoo
Tvardi Therapeutics (NASDAQ: TVRD) registers $200M shelf, $12.5M ATM - Stock Titan
Is Tvardi Therapeutics (TVRD) stock breaking out | Q4 2025: EPS Misses EstimatesInvestment Signal Network - Newser
Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN
TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Tvardi Therapeutics posts 18.3% downside EPS miss amid clinical trial costsEarnings Forecast - Newser
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):